Molecular formula: C225H348N48O68

Molar Mass: 4813.45 g/mol

Purity (HPLC): ≥ 98,6%

Specification: 15 mg/vial, 15 mg injection pen

Tirzepatide is a synthetic peptide and a dual receptor agonist targeting both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This dual action results in powerful synergistic effects on glucose metabolism, insulin sensitivity, and body weight regulation.

It acts by stimulating glucose-dependent insulin secretion, suppressing glucagon production, slowing gastric emptying, and significantly reducing appetite and food intake. Tirzepatide has been shown to be more effective than single-pathway peptides for fat loss and glycemic control, making it one of the most advanced investigational compounds in the metabolic category.

Key Properties of Tirzepatide:

• Dual GIP and GLP-1 receptor activation for superior metabolic regulation

• Powerful appetite suppression and extended satiety

• Significant reduction in body weight and visceral fat

• Enhanced insulin sensitivity and glycemic control

• Positive effect on lipid profiles and cardiometabolic markers

• Long-acting action, suitable for once-weekly subcutaneous injections

For research purposes only.